Décember 2015
TABLE OF CONTENTSCluster's lifeOur member's newsSave the dateCalls for projectsAround our themes

2015 is already completed and many events have marked this year ... including the 7th Private Invstments Day held in early December at Sanofi's headquarters in the Gerland Biodistrict. More than 120 members of the ecosystem were present that day, and not less than 30 investors came to discover the regional health SMEs in which they could make some investment.

The whole Lyonbiopole's team wishes you, through its greeting card, an happy end of year celebrations and gives you an appointment in early 2016 to assist you in your new projects.

Cluster's life

  Aliz Pharma PREMAG project awarded by the LAB MEETING of Bref Rhne-AlpesAmong the 18 projects submitted by nine clusters of the Rhne-Alpes region, two were selected, including Aliz Pharma PREMAG project rewarded during the Awards ceremony evening held on Wednesday, December 9 in Lyon. (...)
 European Project "ASSET"Since 2014, Lyonbiopole is participating to the European project “ASSET”. Its objective is to define an innovative participatory strategy for a better preparedness to epidemics and pandemics. The consortium gathers complementary experiences and knowledge to address effectively scientific and societal challenges raised by pandemics and the associated crisis management. Different studies have been issued during 2015 and the next two years will be dedicated to the implementation of the Strategic Plan. In June 2016 Lyonbiopole is co-organising a Summer School in Rome: “Science in society related issue in pandemics” opened to students and professionals from whole Europe.

Our member's news

 New membersDermadis is a new company in biotechnology, that develops novel assets in the dermatology field. Its unique platform of biologicals with potent inhibitory activities against epidermal kallikreins are of strong interest for the development of medicinal drugs, cosmetics and veterinary products. (...)
 New membersSUBLIMED is a start-up newly created in 2015. It's the result of a two years R&D collaboration between the CEA (Atomic Energy Commission) and the Grenoble Hospital. The founding partners designed a unique product, protected by 5 patents. It is a device of transcutaneous neuro-stimulation (TENS) for chronicle pains treatments, completely innovative in terms of user experience. (...)
 Focus onAAA Reports 37% growth in sales for the 3th quarter of 2015. With the announcement of positive Phase 3 results from the NETTER-1 trial, and the subsequent completion of a successful initial public offering in November, AAA believes to be well positioned to advance the development of our lead drug candidate Lutathera in patients with advanced midgut neuroendocrine tumors. (...)
 Décember 1st, 2015ENYO Pharma strengthens its arsenal of hepatitis B potential therapies Décember 8th, 2015Nosopharm joins ENABLE project Décember 9th, 2015LXRepair and Bertin Pharma sign up an agreement
 Décember 10th, 2015ERYTECH wins the european small and mid-cap award Décember 11th, 2015Adocia and Lilly report positive results Décember 14th, 2015Poxel Announces Imeglimin Phase 2b Initiation in Japan
 Décember 16th, 2015ImmunID Strengthens its Intellectual Property Position in China Décember 22th, 2015Sanofi Pasteur’s dengue vaccine approved in the Philippines

Save the date

  • BIOVISION 2016
    April 13th, 2016

  • See All events

    Calls for projects



  • Eurostars calls
    Before February 18th, 2015
  • Innovative Medicines Initiative - IMI 2
    Before March 16th, 2015
  • H2020 Health Personalised Medicine calls for projects
    Before April 13th, 2016
  • H2020 SME instrument
    Before October 30th, 2016
  • Around our themes

  • INSERM workshop Advanced approaches for fighting bacterial antibiotic resistance
    March 1st, 2016
  • AMP 2016
    June 6th to 8th, 2016
  • Bâtiment Domilyon

    321, avenue Jean Jaurès

    69007 Lyon

    Tel. : +33 (0)4 72 76 53 30

    Fax : +33 (0)9 55 91 30 26





    This email has been sent automatically to [[EMAIL_TO]]. Click here to unsubscribe.